EFFECTS OF A HYPERVOLEMIC HEMODILUTION WITH HES-100 0.5 10-PERCENT INPATIENTS WITH PAOD STAGE-II - ELIMINATION KINETICS AND BLOOD FLUIDITY/

In an open Phase-II study on 10 patients with POAD II the plasmatic el imination, rheological and hemostasiological parameters of a new hydro xyethyl starch with a mean molecular weight of 100,0000 Dalton, a mola r substitution of 0.5 and a C2/C6 substitution ratio of 6.2 (HES 100/0 .5) were determined. Measurements were carried out before and 1, 3, 6, and 24 h after infusion. The mean molecular weight of 100,000 Dalton decreased only slightly up to 24 hours. The plasmatic molecular distri bution width of the HES 100/0.5 was unchanged during the whole period of time - in contrary to other HES-types. The decrease in the hematocr it of 5.5 % is comparable to other HES-types, and is still significant up to 24 h after infusion. Similar effects can be seen for the plasma viscosity. The decrease is about 3 % which is still significant 24 h after infusion (from 1.33 mPas to 1.28 mPas after 24 h). The maximal d ecrease of erythrocyte aggregation is about 26 % (from 23 to 18 one ho ur after infusion), and this effect is still significant 24 h after in fusion. Plasmatic haemostasis is not influenced by hemodilution treatm ent with HES 100/0.5; prothrombin time and partial thromboplastin time remained unchanged. The amount of rheological changes is comparable t o HES 200/0.5 whilst the improvement of blood fluidity is lasting long er. The lack of influence on plasmatic hemostasis could offer advantag es from a hemostasiological point of view. HES 100/0.5 seems to be an interesting variant of a known and proven colloid which however has to be evaluated in further clinical biometrically stringent studies. Cop yright (C) 1996 Elsevier Science Ltd